查看購物車
  • English
  • Japanese
基因改造動物模型市場—全球及區域分析：按技術、動物類型、應用、最終用戶和地區分類—分析與預測（2025-2035）
市場調查報告書
商品編碼
1927582

基因改造動物模型市場—全球及區域分析：按技術、動物類型、應用、最終用戶和地區分類—分析與預測（2025-2035）

Transgenic Animal Model Market - A Global and Regional Analysis: Focus on Technology, Animal Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 164 Pages | 商品交期: 1-5個工作天內

價格

受基因工程技術的進步和對嚴格的臨床前測試日益成長的需求的推動，基因改造動物模型市場正在經歷顯著成長。

基因改造動物，即用其他物種的基因改造的動物，對於研究人類疾病、測試新治療方法和改進農業技術至關重要。這些模型使研究人員能夠模擬人類疾病，從而深入了解疾病機制、遺傳易感性和潛在治療方法的有效性。

關鍵市場統計數據
預測期 2025-2035
2025 年評估 27.96億美元
2035 年預測 67.993億美元
複合年成長率 9.29%

隨著精準醫學領域的發展，基因改造模型在推動個人化醫療方面發揮著至關重要的作用。這些模型使研究人員能夠研究基因對癌症、遺傳性疾病和慢性病的影響，有助於開發更具針對性和更有效的治療方法。隨著CRISPR-Cas9等基因編輯技術的興起，對這些模型的需求日益成長，從而支持開發針對個體基因組成量身定做的治療方法。將這些先進模型整合到研究中，不僅可以加速藥物研發，還可以透過減少治療中的試驗過程來改善病患的治療效果。

市場概覽

全球基因改造動物模型市場預計將迎來顯著成長，到2035年市場規模預計將達到67.993億美元。基因工程技術的進步以及對更精準的臨床前測試需求的不斷成長，推動了基因改造動物模型市場的蓬勃發展。基因改造動物模型是透過將外源基因插入生物體基因組而建構的，在理解複雜疾病和檢驗新治療方法發揮關鍵作用。這些模型使研究人員能夠重現人類疾病，並深入了解疾病機制、遺傳影響以及各種治療方法的有效性。

對個人化醫療日益成長的需求正在推動基因改造模型的應用，這些模型能夠幫助我們更深入地了解遺傳因素如何影響個體的疾病感受性和治療反應。 CRISPR 和次世代定序(NGS) 等技術透過實現更精準的基因修飾和促進建構更精確、更接近人類的模型，加速了這些模型的開發。這在腫瘤學、神經病學和遺傳疾病等領域尤其重要，因為在這些領域，個人化治療的重要性日益凸顯。

此外，人工智慧 (AI) 和巨量資料分析的融合正在改變基因改造模型在研究中的應用方式。這些技術透過預測疾病預後、最佳化治療策略以及提高動物模型的精確度，提升了藥物研發的效率。隨著這些技術的不斷發展，它們將進一步推動基因改造動物模型市場的創新，從而實現更個人化和有效的治療方案。然而，倫理問題、監管複雜性以及建構和維護這些模型的高成本等挑戰仍然限制市場成長。儘管存在這些障礙，基因編輯技術和計算工具的持續進步有望在未來推動市場擴張。

對產業的影響

基因改造動物模型透過推進藥物發現和開發，對生物技術和製藥產業產生了深遠的影響。例如，基因轉殖小鼠在阿茲海默症研究中的應用，為深入了解疾病的遺傳基礎提供了寶貴的見解，並促成了潛在治療方法的測試，例如靶向BETA-澱粉樣蛋白的藥物AduHerm。這些模型使研究人員能夠精確地模擬人類疾病，從而實現更有效的臨床前試驗。

基因工程模型正在提高臨床試驗的可預測性和效率。例如，攜帶人類癌症基因的基因工程小鼠被用於測試免疫療法，例如用於治療白血病的CAR-T療法Kymriah。透過模擬人體反應，這些模型降低了後期臨床試驗失敗的風險。

CRISPR 技術的應用使得基因改造動物模型的開發成為可能，從而可以進行精確的基因編輯，尤其是在鐮狀細胞疾病相關調查中。利用基因轉殖小鼠進行的基因治療試驗已經開展，為 CTX001 等治療方法提供了途徑，目前正在進行臨床試驗。

整體而言，基因改造模型正在加速精準醫療，提高治療效果，最佳化臨床試驗，進而實現更快、更有經濟的藥物研發。

市場區隔:

細分 1：按技術

  • CRISPR/Cas9
  • 顯微注射
  • 胚胎幹細胞注射
  • 其他

截至2024年，CRISPR/Cas9技術在全球基因改造動物模型市場中佔最大佔有率，達到44.96%。 CRISPR/Cas9技術憑藉其基因修飾的精準性、高效性和多功能性，徹底革新了基因改造動物模型市場。與傳統方法不同，CRISPR技術能夠精確地在基因組的特定位置進行基因敲入、敲除和編輯，使其成為更快、更準確、更經濟高效的方法。這大大加速了用於疾病研究、藥物研發和個人化醫療的動物模型的建構。例如，CRISPR技術已成功應用於建構模擬癌症、遺傳疾病和神經退化性疾病等複雜疾病的基因修飾小鼠模型，這些模型被用於測試標靶治療和基因編輯療法。

CRISPR/Cas9市場的快速成長得益於其能夠以比傳統方法更低的成本和更短的時間建立複雜的動物模型。其應用領域正在不斷擴展，涵蓋基因治療、癌症研究和個人化醫療等領域，許多公司和研究機構正利用CRISPR技術建構更精準的模型，用於藥物測試和治療方法的開發。隨著技術的進步，精準度和遞送方式的不斷改進，CRISPR有望進一步加速生物醫學創新，並成為基因研究的關鍵工具。這將使其成為基因改造動物模型市場中成長最快的細分領域。

第二部分：依動物類型

  • 囓齒動物（小鼠和大鼠）
  • 兔子
  • 豬
  • 其他

按動物類型分類，全球基因改造動物模型市場以囓齒類動物為主導，預計到2024年將佔74.96%的市場。囓齒類動物，尤其是小鼠，在基因改造動物模型市場中佔據主導地位，佔生物醫學研究中使用的基因改造動物的95%以上。小鼠之所以成為首選模式生物，是因為它們具有幾個關鍵優勢：可以對其完整的基因組序列進行廣泛分析，並且與人類具有高度的遺傳相似性。這些因素使它們成為研究人類疾病、遺傳失調和藥物反應的理想模型。例如，基因轉殖小鼠被廣泛用於建立阿茲海默症模型，從而可以研究澱粉樣斑塊並測試諸如Aduherm等旨在減少斑塊累積的治療方法。小鼠也被廣泛用於癌症研究，例如敲除p53等基因可以建構模擬人類腫瘤生長的模型，有助於評估CAR-T細胞療法等治療方法。

囓齒類基因改造動物模型市場的成長主要得益於小鼠能夠精準操控基因，並藉助先進技術的支持，使研究人員能夠高精度地模擬人類疾病。此外，小鼠繁殖週期短、易於進行生理和行為測試，且能適應受控的實驗環境，使其成為大規模研究的理想選擇。這些特性，加上小鼠在癌症、神經退化性疾病疾病和代謝性疾病研究中的既有地位，確保了小鼠在基因改造動物模型市場中持續佔據主導地位並保持快速成長。

細分 3：按應用

  • 藥物發現與開發
  • 疾病研究
  • 基因功能研究
  • 毒理學和安全性測試
  • 其他

按應用領域分類，藥物發現與開發領域將主導全球基因改造動物模型市場，預計2024年將佔據54.19%的市場。這是因為該領域是使用這些模型進行臨床前研究的主要用戶，涵蓋從標靶檢驗和作用機制研究到療效篩檢和早期安全性評估等各個環節。製藥公司和領先的生物技術公司不斷增加對基因改造和人源化模型的預算投入，尤其是在腫瘤學、代謝性疾病、神經退化性疾病以及先進治療方法（免疫腫瘤學、基因和細胞療法）等領域，因為這些模型能夠提高轉化相關性並降低後期研發失敗的風險。此外，該領域的研究量龐大，需要持續獲得授權或客製化培育的品系，從而導致持續的支出。與製藥研發管線對接的合約研究組織（CRO）提供的基因改造模型服務進一步簡化了實施流程，並增強了市場需求。因此，藥物發現與開發領域仍是該市場最大且最具商業性價值的需求來源。

細分 4：按最終用戶

  • 製藥和生物技術公司
  • 學術和研究機構
  • 受託研究機構（CRO）

以終端用戶類型分類，製藥和生物技術公司在全球基因改造動物模型市場中佔據主導地位，2024年市佔率達57.38%。製藥和生物技術公司是基因改造動物模型的主要需求來源，其研發活動推動了市場擴張。這些機構依賴基因工程動物來降低研發風險，檢驗藥物標靶，闡明疾病通路，產生療效和安全性數據，並在首次人體臨床試驗前最佳化給藥方案。例如，在腫瘤學領域，人源化基因轉殖小鼠常用於評估免疫腫瘤候選藥物，而兔子和豬等體型較大的基因轉殖動物則用於支持需要類似人類生理功能的心血管和代謝研究。精準醫療、生物製藥以及基因和細胞療法的加速發展加劇了這種需求，因為這些治療方法通常針對人類特有的通路，而這些通路無法在體外進行充分模擬。同時，大型製藥公司正委託開發客製化的基因改造品系，以模擬罕見疾病、多因子疾病和兒童疾病，從而提高臨床成功率，並滿足監管機構對疾病相關臨床前數據的要求。先進技術的取得、對轉化可靠數據的需求以及日益嚴格的監管審查，共同推動了製藥和生物技術公司成為基因改造動物模型市場成長和創新的核心驅動力。

細分5：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 澳洲
    • 韓國
    • 其他
  • 其他地區

北美憑藉著多項結構性優勢，在基因改造動物模型市場佔據主導地位。該地區擁有全球最高的生物製藥研發活動密度，並擁有健全的法規環境，有利於創新。美國和加拿大的眾多製藥和生物技術公司正在推進腫瘤、感染疾病和代謝性疾病等關鍵治療領域的高通量臨床前研發管線。在這些領域，基因改造和人源化動物模型對於在臨床試驗前獲得可靠的體內數據至關重要。美國食品藥物管理局（FDA）和加拿大衛生署等監管機構積極參與新興治療方法，例如mRNA療法、個人化癌症疫苗和呼吸道合胞病毒（RSV）疫苗，從而推動了對符合嚴格證據標準的高預測性動物模型的需求。此外，北美在生產基礎設施、自動化和符合GMP規範的工作流程方面的投資也延伸至臨床前運營，從而能夠快速創建和部署客製化的基因改造品系，包括疾病特異性和人源化模型。

該地區慢性病高發，加上精準醫療和細胞基因療法的早期應用，推動了對能夠重現人類生物學路徑的動物模型的需求。此外，北美擁有雄厚的財力、密集的受託研究機構（CRO）生態系統，以及主導機構對高品質數據的需求，這些因素共同促成了北美成為基因改造動物模型市場的戰略中心。

基因改造動物模型市場的最新趨勢

  • 2025 年 8 月，Taconic Biosciences 與 Cyagen Biosciences 合作，為臨床前研究人員提供更廣泛、更有效率的途徑，取得 Cyagen 超過 16,000 種基因工程小鼠模型的龐大庫。
  • 2025 年 7 月，百奧賽圖製藥公司宣布對其臨床前業務部門進行重大改進，包括擴大基因工程動物模型組合，包括靶向人源化小鼠、免疫人源化小鼠、基因改造小鼠和免疫力缺乏小鼠，以及全面的臨床前服務，包括療效測試、PK/PD 分析、生物標記評估和非 GLP 毒理學測試。
  • 2024年10月，Alloy Therapeutics與史克里普斯研究所簽署了一項機構授權合約，授權其使用ATX-Gx平台。該平台能夠生成全人源抗體。這項非獨家授權將使史克里普斯研究所的所有研究人員都能使用ATX-Gx平台進行抗體醫藥品和疫苗的研發。
  • 2024年6月，百奧賽圖公司（Biocytogen）的RenLite平台獲得美國專利。該平台能夠建構具有通用輕鏈的全人源抗體，從而簡化雙特異性抗體和抗體藥物偶聯物（ADC）的開發。這項創新技術提高了抗體的多樣性，並簡化了CMC製程。

需求——促進因素、挑戰與機遇

市場需求促進因素：醫藥研發活動增加

對藥物研發日益重視是基因改造動物模型市場的主要驅動力。隨著產業朝著更具針對性和更有效的治療方法發展，對基因改造動物的需求顯著成長。這些基因改造模型對於應對現代藥物研發的複雜性至關重要，尤其是在個人化醫療和精準治療等領域。基因改造動物能夠模擬人類疾病的生物學特性，使研究人員能夠在與人類疾病環境高度相似的環境中測試治療方法。例如，在愛滋病研究中，研究人員會使用人源化小鼠來評估抗逆轉錄病毒藥物在臨床試驗前的療效。

隨著製藥業不斷推進藥物研發，提高藥物發現的速度和精準度，對能夠預測人體反應的模型的需求也日益成長。基因改造動物模型對於研究傳統模型無法重現的疾病至關重要，例如癌症、神經退化性疾病疾病和心血管疾病。例如，p53基因敲除小鼠被用於癌症研究，以探討腫瘤進展並測試靶向突變基因的治療方法；而表達人類Tau蛋白的基因改造小鼠則在阿茲海默症研究中發揮重要作用。對創新藥物和生物製藥研發投入的不斷增加，進一步推動了對這些模型的需求，這些模型對於理解疾病機制、測試新型化合物以及評估治療方法的安全性和有效性至關重要。

市場挑戰－動物模型的高昂維修成本

基因改造動物模型市場面臨的一大挑戰是高昂的維修成本。從育種到實驗應用，開發和維護這些模型都需要在各個階段投入大量資金。飼養這些動物需要專門的環境控制設施，與傳統模型相比，這會增加資本和營運成本。基因改造動物需要先進的基因工程技術、持續監測，通常需要多代育種，這導致開發週期延長，並增加了遺傳學家和獸醫等專業人員的勞動力成本。

例如，僅購買C57BL/6近交系小鼠的成本可能超過3500美元，這還不包括籠具維護、獸醫護理以及顯微注射和胚胎移植等特殊操作的費用。這些基因改造動物需要無菌環境和特殊護理，進一步增加了持續營運成本。雖然雜交品係可以降低部分成本，但建造和維護基因改造模型的總體成本仍然是小規模實驗室和Start-Ups企業的一大障礙，限制了市場成長。

因此，像輝瑞和諾華這樣的大型製藥公司能夠承擔高成本，而規模較小的生物技術公司和學術實驗室則被迫依賴細胞分析和電腦模擬等替代模型。這種資金壁壘減緩了市場擴張，尤其對規模較小的參與企業而言更是如此。

市場機會－CRISPR技術在生物醫學研究中的崛起

CRISPR技術的出現徹底改變了生物醫學研究中基因改造動物模型的建構和效用，實現了快速、精準、高效的基因組編輯。 CRISPR/Cas9技術使研究人員能夠以遠高於傳統方法（例如胚胎幹細胞同源重組）的精度和成本效益，在從小鼠到豬、羊、雞等大型動物的各種動物中構建靶向基因敲除、敲入和點突變模型。 CRISPR加速了大小動物疾病模型的構建，這些模型能夠忠實地模擬人類病理，包括神經退化性疾病、心血管疾病、囊腫纖維化和癌症。這些模型能夠更可靠地幫助闡明疾病機制和篩檢治療方法。此外，CRISPR技術還能夠進行複雜的基因操作，包括同時編輯多個基因，從而建立多基因疾病模型並研究基因交互作用。

CRISPR 將促進生物反應器動物的生產，例如基因工程改造的雞可以在雞蛋中生產藥用蛋白，或者基因工程改造的動物可以生產抗體，從而擴大工業和治療應用，並能夠開發具有抗病能力的基因改造動物（例如抗病毒家禽），從而支持食品安全和生物醫學研究。

除了基因編輯外，CRISPR 還應用於再生醫學、組織工程和表觀基因編輯，可以在不改變 DNA 序列的情況下調節基因表現，以及基於 CRISPR 的診斷工具，如 SHERLOCK 和 DETECTR，用於快速靈敏地檢測病毒感染和基因突變。

市場趨勢－個人化醫療需求不斷成長

個人化醫療的日益普及顯著增加了藥物發現和治療方法開發中對基因改造動物模型（尤其是人源化小鼠）的需求。隨著治療方案越來越貼合個體的基因譜，基因改造模型對於測試基因療法、免疫療法和患者特異性藥物方案至關重要。透過基因工程改造表達人類基因和突變的人源化小鼠模型，研究人員能夠更精確地研究人類疾病，並更有效地預測治療結果。

這些模型對於基因療法至關重要，例如反義寡核苷酸（ASO），用於沉默阿茲海默症、亨廷頓舞蹈症和肌萎縮側索硬化症（ALS）等神經退化性疾病中的有害基因。利用人源化小鼠的成功研究表明，疾病相關基因的表達降低，症狀得到改善。此外，將CRISPR/Cas9技術與基因改造模型結合，可實現標靶基因編輯。例如，研究表明，降低ALS小鼠體內hSOD1的水平可以延緩疾病進展，為未來的基因編輯療法鋪平道路。

基因轉殖模型在免疫療法試驗中也發揮重要作用，例如CAR-T細胞療法和標靶人類特異性蛋白的抗體療法。例如，具有人類免疫系統的人源化小鼠被用於評估癌症和阿茲海默症研究中的免疫反應。同樣，透過將人類腫瘤組織移植到小鼠體內而建構的患者來源異種移植模型（PDX模型）有助於評估個人化療法如何與患者獨特的基因組成相適應。

隨著個人化醫療的不斷發展，基因改造動物模型已成為基因標靶治療開發的關鍵，能夠更深入地了解人類疾病的多樣性，簡化藥物發現過程，並支持開發更安全、更有效的、針對個別患者的治療方法。

本報告深入分析了基因改造動物模型的最新技術趨勢，使各組織能夠推動創新並開發滿足市場需求的尖端產品。

透過全面的市場分析和對關鍵成長機會的識別，我們為企業提供製定有針對性的行銷策略和有效擴大市場佔有率所需的知識。

競爭策略：該報告包含全面的競爭格局分析，以幫助企業了解競爭對手的優勢和劣勢，並制定有效的策略以獲得市場競爭優勢。

我們提供有關不斷變化的法規結構、核准流程和行業指南的最新資訊，以確保您的組織保持合規，並加快新型基因改造動物模型產品的市場准入。

投資和業務擴大策略：透過分析市場趨勢、資金籌措模式和合作機會，我們幫助企業做出明智的投資決策，並識別潛在的併購機會以促進業務成長。

調查方法

市場設計與檢驗中的關鍵考慮因素與假設

  • 計算市場規模的基準年設定為2024年。對2021會計年度至2023會計年度期間的歷史表現進行了分析。估算了2024會計年度的市場規模，並對2025會計年度至2035會計年度期間的市場規模進行了預測。
  • 本報告的研究範圍是基於與全球企業專家的對話而精心製定的。本報告提供關於CRISPR/Cas9、顯微注射、胚胎幹細胞注射和其他基因改造動物模型技術的市場研究。
  • 各公司的收入均以 2023 會計年度及 2024 會計年度的年度報告為依據。對於私人公司，其收入是根據一手調查資訊、資金籌措歷史、市場合作和業務表現等因素估算得出的。
  • 本報告基於現有的基因改造動物模型解決方案繪製了市場圖。報告中涵蓋並介紹了該領域所有提供重要產品和服務的主要企業。

主要市場參與企業及競爭格局概述

我們根據對公司覆蓋範圍、產品系列和市場滲透率的分析，並結合從行業領先專家那裡收集的資訊，來選擇對其中進行介紹的公司。

該市場的一些主要企業包括：

  • Charles River Laboratories International, Inc.
  • Creative Biolabs
  • Alloy Therapeutics, Inc.
  • Inotiv.
  • HuidaGene
  • genOway
  • Ingenious Targeting Laboratory
  • OmniAb Inc.
  • Taconic Biosciences
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd
  • Merck Group
  • Janvier Group

目錄

執行摘要

第1章 全球基因改造動物模型市場：產業展望

  • 市場概覽
    • 市場概覽與生態系統
  • 市場趨勢
    • 影響分析
    • 對個人化醫療的需求日益成長
  • 監管狀態
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區
  • 定價分析
    • 產生成本（建立新模型）
    • 購置成本（購買現有型號）
    • 額外費用
  • 技術展望
  • 市場動態
    • 促進因素、挑戰和機會：評估當前和未來的影響
    • 市場促進因素
    • 市場限制
    • 市場機遇

第2章：技術

  • 概述
    • CRISPR/Cas9
    • 顯微注射
    • 胚胎幹細胞注射
    • 其他

第3章 動物種類

  • 概述
    • 囓齒動物（小鼠和大鼠）
    • 兔子
    • 豬
    • 其他

第4章 應用

  • 概述
    • 藥物發現與開發
    • 疾病研究
    • 基因功能研究
    • 毒理學和安全性測試
    • 其他

第5章 最終用戶

  • 概述
    • 製藥和生物技術公司
    • CRO
    • 學術研究機構

第6章 區域

  • 區域概況
  • 北美洲
    • 區域概覽
    • 市場成長促進因素
    • 成長抑制因素
    • 市場規模及預測
    • 美國
    • 加拿大
  • 歐洲
    • 區域概覽
    • 市場成長促進因素
    • 成長抑制因素
    • 市場規模及預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 區域概覽
    • 市場成長促進因素
    • 成長抑制因素
    • 市場規模及預測
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 其他地區
    • 區域概覽
    • 市場成長促進因素
    • 成長抑制因素
    • 市場規模及預測

第7章 競爭標桿分析與公司概況

  • 關鍵策略與發展（2023-2025）
  • 公司關鍵發展分析（2023-2025）
  • 公司簡介
    • Charles River Laboratories International, Inc.
    • Creative Biolabs
    • Alloy Therapeutics, Inc.
    • Inotiv.
    • Ingenious Targeting Laboratory.
    • HuidaGene
    • genOway
    • OmniAb, Inc.
    • Taconic Biosciences
    • Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'
    • Sigma-Aldrich Co. (Merck Group)
    • Janvier Group (Janvier Labs)

第8章調查方法

Product Code: BHL3200SA

This report can be delivered within 1 working day.

Introduction of Transgenic Animal Model

The transgenic animal model market is experiencing significant growth, driven by advancements in genetic engineering and the increasing need for precise preclinical testing. Transgenic animals, modified to carry genes from other species, are crucial for studying human diseases, testing new therapies, and improving agricultural practices. These models help researchers simulate human diseases, providing insights into disease mechanisms, genetic predispositions, and the effects of potential treatments.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$2,796.0 Million
2035 Forecast$6,799.3 Million
CAGR9.29%

As the field of precision medicine evolves, transgenic models play a key role in advancing personalized healthcare. By enabling researchers to study genetic influences on diseases like cancer, inherited disorders, and chronic conditions, these models help create more targeted, effective treatments. With the rise of gene-editing technologies such as CRISPR-Cas9, the demand for these models is growing, supporting the development of therapies tailored to an individual's genetic makeup. The integration of these advanced models into research not only accelerates drug development but also improves patient outcomes by reducing the trial-and-error approach to treatment.

Market Introduction

The global transgenic animal model market is expected to witness substantial growth, projected to reach $6,799.3 million by 2035. The transgenic animal model market is witnessing substantial growth, fueled by advancements in genetic engineering and the increasing need for more accurate preclinical testing. Transgenic animal models, created by inserting foreign genes into an organism's genome, play a crucial role in understanding complex diseases and testing new therapeutic interventions. These models enable researchers to simulate human diseases, providing insights into disease mechanisms, genetic influences, and the effects of various treatments.

The growing demand for personalized medicine is driving the adoption of transgenic models, as they allow for a deeper understanding of how genetic factors contribute to individual disease susceptibility and treatment response. Technologies like CRISPR and next-generation sequencing (NGS) are accelerating the development of these models by enabling more precise genetic modifications, facilitating the creation of more accurate and human-like models. This is particularly important in areas such as oncology, neurology, and genetic disorders, where personalized treatments are gaining prominence.

Moreover, the integration of artificial intelligence (AI) and big data analytics is transforming how transgenic models are used in research. These technologies enhance the efficiency of drug development processes by predicting disease outcomes, optimizing treatment strategies, and improving the precision of animal models. As these technologies continue to evolve, they will drive further innovation in the transgenic animal model market, enabling more tailored and effective therapeutic solutions. However, challenges such as ethical concerns, regulatory complexities, and the high cost of creating and maintaining these models continue to impact the market's growth. Despite these hurdles, the continued advancements in gene-editing technologies and computational tools are expected to fuel the future expansion of the market.

Industrial Impact

Transgenic animal models are significantly impacting the biotechnology and pharmaceutical industries by advancing drug discovery and development. For example, the use of transgenic mice in Alzheimer's research has provided valuable insights into the disease's genetic underpinnings, leading to the testing of potential therapies like the amyloid-beta-targeting drug Aduhelm. These models help researchers simulate human diseases accurately, enabling more effective preclinical testing.

In clinical trials, transgenic models improve predictability and efficiency. For instance, genetically modified mice with human cancer genes have been used to test immunotherapies like Kymriah, a CAR-T therapy developed for leukemia. By mimicking human responses, these models reduce the risk of failure in later trial stages.

The use of CRISPR technology has enhanced transgenic animal models, allowing precise gene edits. This is particularly evident in research related to sickle cell disease, where transgenic mice have been used to test gene therapies, providing a path for treatments like CTX001, which is currently in clinical trials for sickle cell anemia.

Overall, transgenic models are accelerating precision medicine, improving therapeutic efficacy, and optimizing clinical trials, leading to faster, more cost-effective drug development.

Market Segmentation:

Segmentation 1: By Technology

  • CRISPR/CAS-9
  • Microinjections
  • Embryonic Stem Cell Injections
  • Others

In the global transgenic animal model market, as of 2024, the CRISPR/CAS9 segment holds the largest share at 44.96%. CRISPR/Cas9 has revolutionized the transgenic animal model market due to its precision, efficiency, and versatility in genetic modifications. Unlike traditional methods, CRISPR allows for precise gene knock-ins, knockouts, and edits at specific locations in the genome, making it faster, more accurate, and cost-effective. This has significantly accelerated the creation of animal models used in disease research, drug discovery, and personalized medicine. For example, CRISPR has enabled the development of genetically modified mice to model complex diseases like cancer, genetic disorders, and neurodegenerative diseases, which can be used to test targeted therapies and gene-editing treatments.

The rapid growth of the CRISPR/Cas9 market is driven by its ability to generate complex animal models quickly and at a lower cost compared to traditional methods. Its applications in areas such as gene therapy, cancer research, and personalized medicine are expanding, as companies and research institutions use CRISPR to create more accurate models for drug testing and therapeutic development. As the technology continues to advance, with improvements in precision and delivery, CRISPR is expected to further accelerate the pace of biomedical innovation, making it the dominant tool in genetic research and driving its fastest growth in the transgenic animal model market.

Segmentation 2: By Animal Type

  • Rodent (Mice & Rats)
  • Rabbits
  • Pigs
  • Others

Based on animal type, the global transgenic animal model market was led by the rodent segment, which held a 74.96% share in 2024. Rodents, particularly mice, dominate the transgenic animal model market, with over 95% of transgenic animals used in biomedical research being rodents. The mouse is the model organism of choice due to several key advantages: the extensive analysis of its completed genome sequence and its genetic similarity to humans. These factors make mice ideal for studying human diseases, genetic disorders, and drug responses. For instance, genetically modified mice are extensively used to model Alzheimer's disease, enabling the study of amyloid plaques and the testing of therapies like Aduhelm, a drug aimed at reducing plaque buildup. Mice are also commonly used in cancer research, where genes like p53 are knocked out to create models mimicking human tumor growth, facilitating the evaluation of treatments such as CAR-T cell therapy.

The growth of the rodent-based transgenic animal model market is driven by the mouse's ability to undergo precise genetic manipulation, supported by robust and sophisticated techniques. This allows researchers to replicate human diseases with high accuracy. Additionally, mice's short reproduction cycle, ability to perform physiologic and behavioral tests, and their adaptability to controlled laboratory environments make them perfect for large-scale studies. These characteristics, combined with their established role in studying diseases like cancer, neurodegenerative disorders, and metabolic diseases, ensure their continued dominance and rapid growth in the transgenic animal model market.

Segmentation 3: By Application

  • Drug Discovery and Development
  • Disease Research
  • Gene Function Studies
  • Toxicology and Safety Testing
  • Others

Based on application type, the drug discovery and development segment dominated the global transgenic animal model market with 54.19% share in 2024 because it is the primary user segment that applies these models across the full preclinical workflow from target validation and MoA studies to efficacy screening and early safety. Pharmaceutical and large biotechnology companies continue to allocate higher budgets to transgenic and humanized models, particularly for oncology, metabolic disorders, neurodegenerative diseases, and advanced modalities (immuno-oncology, gene and cell therapies), as these models improve translational relevance and help lower late-stage failure risk.Moreover, this segment also operates at higher study volumes and requires continuous access to licensed or custom-bred strains, which drives recurring spend. The availability of CRO-delivered, transgenic model services tailored to pharma pipelines has further streamlined adoption and reinforced demand. As a result, the drug discovery and development segment remains the largest and most commercially significant demand center in this market.

Segmentation 4: By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)

Based on end user type, the pharmaceutical and biotechnology companies dominated the global transgenic animal model market with 57.38% share in 2024. Pharmaceutical and biotechnology companies are the principal demand centers for transgenic animal models, and their R&D activity is the single largest contributor to market expansion. These organizations rely on genetically engineered animals to de-risk development - validating drug targets, interrogating disease pathways, generating efficacy and safety data, and refining dose regimens prior to first-in-human studies. In oncology, for instance, humanized transgenic mice are routinely used to evaluate immuno-oncology candidates, while larger transgenic species such as rabbits and pigs support cardiovascular and metabolic programs where physiology closer to humans is required. The accelerating shift toward precision medicine, biologics, and gene and cell therapies has amplified this need, because these modalities often target human-specific pathways that cannot be modeled adequately in vitro. At the same time, leading pharma players are commissioning bespoke transgenic lines to mirror rare, multifactorial, or pediatric diseases, thereby improving the probability of clinical success and meeting regulatory expectations for disease-relevant preclinical evidence. Together, factors such as sophisticated technology use, demand for translationally credible data, and tighter regulatory scrutiny position pharma and biotech companies as the core engines of growth and innovation in the transgenic animal model market.

Segmentation 5: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

North America maintains a dominant position in the transgenic animal model market due to several structural advantages. The region is home to the largest concentration of biopharma R&D activity, supported by a robust regulatory environment that fosters innovation. A significant number of U.S. and Canadian pharmaceutical and biotechnology companies are driving high-throughput preclinical pipelines in key therapeutic areas such as oncology, infectious disease, and metabolic disorders fields where transgenic and humanized animal models are essential for generating reliable in vivo data prior to clinical trials. Regulatory agencies like the FDA and Health Canada actively engage with emerging therapeutic modalities, including mRNA, personalized cancer vaccines, and RSV vaccines, which has spurred demand for more predictive animal models that meet stringent evidentiary standards. Additionally, North America's investment in manufacturing infrastructure, automation, and GMP-compliant workflows extends to preclinical operations, allowing for the rapid creation and deployment of custom transgenic lines, including disease-specific and humanized models.

The region's high burden of chronic diseases, coupled with its early adoption of precision medicine and cell/gene therapies, further drives the need for animal models that replicate human biological pathways. This convergence of strong capital availability, a dense ecosystem of contract research organizations (CROs), and a regulator-driven push for higher-quality data positions North America as the strategic epicenter of the transgenic animal model market.

Recent Developments in the Transgenic Animal Model Market

  • In August 2025, Taconic Biosciences, collaborated with Cyagen Biosciences to offer preclinical researchers broader and more streamlined access to Cyagen's extensive library of over 16,000 genetically engineered mouse models.
  • In July 2025, Biocytogen Pharmaceuticals announced a major upgrade to its preclinical business division. The enhancement includes a broadened range of genetically engineered animal models such as target-humanized, immune-humanized, transgenic, and immunodeficient mice along with comprehensive preclinical services, including efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing.
  • In October 2024, Alloy Therapeutics entered into an institutional licensing agreement with Scripps Research for its ATX-Gx platform, which enables fully human antibody discovery. This non-exclusive license allows all Scripps Research scientists to use the ATX-Gx platform in their antibody drug and vaccine development efforts
  • In June 2024, Biocytogen received a U.S. patent for its RenLite platform, which enables the creation of fully human antibodies with a common light chain, thereby simplifying the development of bispecific antibodies and ADCs. This innovation enhances antibody diversity and simplifies CMC processes.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers: Growing Number of Pharmaceutical Research and Drug Development Activities

The growing focus on pharmaceutical research and drug development is a key driver for the transgenic animal model market. As the industry shifts toward more targeted and effective therapies, the demand for transgenic animals has significantly increased. These genetically modified models are essential for addressing the complexities of modern drug development, especially in fields like personalized medicine and precision therapies. Transgenic animals simulate human disease biology, enabling researchers to test treatments in environments that closely resemble human conditions. For instance, humanized mice are used in HIV research to evaluate antiretroviral drugs before clinical trials.

With the pharmaceutical industry pushing for faster, more accurate drug discovery, the need for models that predict human responses has intensified. Transgenic animal models are critical for studying diseases that traditional models cannot replicate, such as cancer, neurodegenerative diseases, and cardiovascular disorders. For example, p53 knockout mice are used in cancer research to investigate tumor progression and test therapies targeting mutated genes, while transgenic mice expressing human tau proteins help study Alzheimer's disease. The increased investment in innovative drug and biologic research further fuels the demand for these models, which are indispensable in understanding disease mechanisms, testing new compounds, and assessing the safety and efficacy of treatments.

Market Challenges: High Maintenance Cost of Animal Models

High maintenance costs represent a major challenge in the transgenic animal model market. The development and upkeep of these models require significant financial investment at every stage, from breeding to experimental use. Specialized facilities with controlled environments are needed to house the animals, driving up capital and operational expenses compared to conventional models. Transgenic animals also demand advanced genetic engineering, continuous monitoring, and often multiple breeding generations, which extends timelines and increases labor costs for skilled professionals like geneticists and veterinarians.

For example, maintaining inbred C57BL/6 mice can cost upwards of $3,500 for animal purchase alone, excluding additional expenses for cage upkeep, veterinary care, and specialized procedures like microinjections or embryo transfers. These genetically modified animals require pathogen-free conditions and expert care, adding further to ongoing costs. While hybrid strains can lower some expenses, the overall financial burden of creating and maintaining transgenic models is prohibitive for smaller labs or startups, limiting market growth.

As a result, larger pharmaceutical companies like Pfizer or Novartis can afford the high costs for research, but smaller biotech firms and academic labs often turn to alternative models, such as cell-based assays or computational simulations. This financial barrier slows the market's expansion, especially among smaller players.

Market Opportunities: Emergence of CRISPR as a Powerful Tool for Biomedical Research Field

The emergence of CRISPR technology has revolutionized the creation and utility of transgenic animal models in biomedical research by enabling rapid, precise, and efficient genome editing. CRISPR/Cas9 allows researchers to generate targeted gene knockouts, knock-ins, and point mutations in animals ranging from mice to large species such as pigs, sheep, and chickens with much higher accuracy and lower cost compared to older methods such as homologous recombination in embryonic stem cells. CRISPR accelerates the development of disease models that closely mimic human pathologies, such as neurodegenerative disorders, cardiovascular disease, cystic fibrosis, and cancer, in animals large and small. These models help elucidate disease mechanisms and screen therapies more reliably. It enables complex genetic manipulations, including simultaneous editing of multiple genes, creating models for polygenic diseases or studying gene interactions.

CRISPR facilitates the production of bioreactor animals; for example, chickens engineered to produce pharmaceutical proteins in eggs or animals engineered for antibody manufacturing, which expands industrial and therapeutic applications. It allows the development of transgenic animals with disease resistance (e.g., virus-resistant poultry), supporting both food security and biomedical research.

Beyond gene editing, CRISPR is applied in regenerative medicine, tissue engineering, and epigenome editing, allowing the modulation of gene expression without changing DNA sequences. It is also employed in CRISPR-based diagnostic tools, such as SHERLOCK and DETECTR, which provide rapid and highly sensitive detection of viral infections and genetic mutations.

Market Trends: Rising Demand for Personalized Medicine

The growing emphasis on personalized medicine is significantly increasing demand for transgenic animal models, especially humanized mice, in drug discovery and therapeutic development. As treatments become more tailored to an individual's genetic profile, transgenic models are essential for testing gene therapies, immunotherapies, and patient-specific drug regimens. Humanized mouse models-engineered to express human genes or mutations-allow researchers to study human diseases with higher accuracy and predict treatment outcomes more effectively.

These models are crucial in gene-based therapies like antisense oligonucleotides (ASOs), used to silence harmful genes in neurodegenerative diseases such as Alzheimer's, Huntington's, and ALS. Successful studies in humanized mice have shown reduced disease-related gene expression and symptom improvement. Additionally, integrating CRISPR/Cas9 technology with transgenic models enables targeted gene correction, such as reducing hSOD1 levels in ALS mice to delay disease progression-paving the way for future gene-editing therapies.

Transgenic models also play a vital role in testing immunotherapies like CAR-T cells and antibody-based treatments that target human-specific proteins. For instance, humanized mice with human immune systems are used to evaluate immune responses in cancer and Alzheimer's research. Similarly, patient-derived xenograft (PDX) models-created by implanting human tumor tissues into mice-help assess how personalized therapies perform against a patient's unique genetic makeup.

As personalized medicine continues to evolve, transgenic animal models have become indispensable for developing genetically targeted therapies. They enable deeper insights into human disease diversity, streamline drug development, and support the creation of safer, more effective treatments tailored to individual patients.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in transgenic animal model, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new transgenic animal model products.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2021-FY2023 The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of CRISPR/CAS-9, Microinjections, Embryonic stem cell injections and other technology of the transgenic animal model market.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available transgenic animal model solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in transgenic animal model including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players of the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Charles River Laboratories International, Inc.
  • Creative Biolabs
  • Alloy Therapeutics, Inc.
  • Inotiv.
  • HuidaGene
  • genOway
  • Ingenious Targeting Laboratory
  • OmniAb Inc.
  • Taconic Biosciences
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd
  • Merck Group
  • Janvier Group

Table of Contents

Executive Summary

Scope and Definition

1 Global Transgenic Animal Model Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Market Overview and Ecosystem
  • 1.2 Market Trends
    • 1.2.1 Impact Analysis
    • 1.2.2 Rising Demand for Personalized Medicine
  • 1.3 Regulatory Landscape
    • 1.3.1 North America
      • 1.3.1.1 U.S.
    • 1.3.2 Europe
      • 1.3.2.1 Germany
      • 1.3.2.2 U.K.
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
    • 1.3.4 Rest-of-the-World
  • 1.4 Pricing Analysis
    • 1.4.1 Generation Costs (Creating New Models)
    • 1.4.2 Acquisition Costs (Purchasing Existing Models)
    • 1.4.3 Additional Costs
  • 1.5 Technology Landscape
  • 1.6 Market Dynamics
    • 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.6.2 Market Drivers
      • 1.6.2.1 Growing Number of Pharmaceutical Research and Drug Development Activities
      • 1.6.2.2 Technological Advancements in Genetic Engineering
      • 1.6.2.3 Increasing Demand for Advanced Disease Models for Drug Discovery
    • 1.6.3 Market Restraints
      • 1.6.3.1 High Maintenance Cost of Animal Models
      • 1.6.3.2 Strict Regulations and Guidelines
    • 1.6.4 Market Opportunities
      • 1.6.4.1 Emergence of CRISPR as a Powerful Tool for Biomedical Research Field
      • 1.6.4.2 Increasing Demand for Disease-Specific Models

2 Technology

  • 2.1 Overview
    • 2.1.1 CRISPR/Cas9
    • 2.1.2 Microinjection
    • 2.1.3 Embryonic Stem Cell Injections
    • 2.1.4 Other Technologies

3 Animal Type

  • 3.1 Overview
    • 3.1.1 Rodents (Mice and Rats)
    • 3.1.2 Rabbits
    • 3.1.3 Pigs
    • 3.1.4 Other Animal Types

4 Application

  • 4.1 Overview
    • 4.1.1 Drug Discovery and Development
    • 4.1.2 Disease Research
    • 4.1.3 Gene Function Studies
    • 4.1.4 Toxicology and Safety Testing
    • 4.1.5 Other Applications

5 End User

  • 5.1 Overview
    • 5.1.1 Pharmaceutical and Biotechnology Companies
    • 5.1.2 Contract Research Organizations (CROs)
    • 5.1.3 Academic and Research Institutes

6 Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Market Sizing and Forecast
      • 6.2.4.1 North America Transgenic Animal Model Market, by Technology
      • 6.2.4.2 North America Transgenic Animal Model Market, by Animal Type
      • 6.2.4.3 North America Transgenic Animal Model Market, by Application
      • 6.2.4.4 North America Transgenic Animal Model Market, by End User
      • 6.2.4.5 North America Transgenic Animal Model Market, by Country
    • 6.2.5 U.S.
      • 6.2.5.1 Country Overview
      • 6.2.5.2 U.S. Transgenic Animal Model Market, by Technology
      • 6.2.5.3 U.S. Transgenic Animal Model Market, by Animal Type
      • 6.2.5.4 U.S. Transgenic Animal Model Market, by Application
      • 6.2.5.5 U.S. Transgenic Animal Model Market, by End User
    • 6.2.6 Canada
      • 6.2.6.1 Country Overview
      • 6.2.6.2 Canada Transgenic Animal Model Market, by Technology
      • 6.2.6.3 Canada Transgenic Animal Model Market, by Animal Type
      • 6.2.6.4 Canada Transgenic Animal Model Market, by Application
      • 6.2.6.5 Canada Transgenic Animal Model Market, by End User
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Market Sizing and Forecast
      • 6.3.4.1 Europe Transgenic Animal Model Market, by Technology
      • 6.3.4.2 Europe Transgenic Animal Model Market, by Animal Type
      • 6.3.4.3 Europe Transgenic Animal Model Market, by Application
      • 6.3.4.4 Europe Transgenic Animal Model Market, by End User
      • 6.3.4.5 Europe Transgenic Animal Model Market, by Country
    • 6.3.5 U.K.
      • 6.3.5.1 Country Overview
      • 6.3.5.2 U.K. Transgenic Animal Model Market, by Technology
      • 6.3.5.3 U.K. Transgenic Animal Model Market, by Animal Type
      • 6.3.5.4 U.K. Transgenic Animal Model Market, by Application
      • 6.3.5.5 U.K. Transgenic Animal Model Market, by End User
    • 6.3.6 Germany
      • 6.3.6.1 Country Overview
      • 6.3.6.2 Germany Transgenic Animal Model Market, by Technology
      • 6.3.6.3 Germany Transgenic Animal Model Market, by Animal Type
      • 6.3.6.4 Germany Transgenic Animal Model Market, by Application
      • 6.3.6.5 Germany Transgenic Animal Model Market, by End User
    • 6.3.7 France
      • 6.3.7.1 Country Overview
      • 6.3.7.2 France Transgenic Animal Model Market, by Technology
      • 6.3.7.3 France Transgenic Animal Model Market, by Animal Type
      • 6.3.7.4 France Transgenic Animal Model Market, by Application
      • 6.3.7.5 France Transgenic Animal Model Market, by End User
    • 6.3.8 Italy
      • 6.3.8.1 Country Overview
      • 6.3.8.2 Italy Transgenic Animal Model Market, by Technology
      • 6.3.8.3 Italy Transgenic Animal Model Market, by Animal Type
      • 6.3.8.4 Italy Transgenic Animal Model Market, by Application
      • 6.3.8.5 Italy Transgenic Animal Model Market, by End User
    • 6.3.9 Spain
      • 6.3.9.1 Country Overview
      • 6.3.9.2 Spain Transgenic Animal Model Market, by Technology
      • 6.3.9.3 Spain Transgenic Animal Model Market, by Animal Type
      • 6.3.9.4 Spain Transgenic Animal Model Market, by Application
      • 6.3.9.5 Spain Transgenic Animal Model Market, by End User
    • 6.3.10 Rest-of-the- Europe
      • 6.3.10.1 Country Overview
      • 6.3.10.2 Rest of the Europe Transgenic Animal Model Market, by Technology
      • 6.3.10.3 Rest of the Europe Transgenic Animal Model Market, by Animal Type
      • 6.3.10.4 Rest of the Europe Transgenic Animal Model Market, by Application
      • 6.3.10.5 Rest of the Europe Transgenic Animal Model Market, by End User
  • 6.4 Asia Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Market Sizing and Forecast
      • 6.4.4.1 Asia Pacific Transgenic Animal Model Market, by Technology
      • 6.4.4.2 Asia Pacific Transgenic Animal Model Market, by Animal Type
      • 6.4.4.3 Asia Pacific Transgenic Animal Model Market, by Application
      • 6.4.4.4 Asia Pacific Transgenic Animal Model Market, by End User
      • 6.4.4.5 Asia PacificTransgenic Animal Model Market, by Country
    • 6.4.5 China
      • 6.4.5.1 Country Overview
      • 6.4.5.2 China Transgenic Animal Model Market, by Technology
      • 6.4.5.3 China Transgenic Animal Model Market, by Animal Type
      • 6.4.5.4 China Transgenic Animal Model Market, by Application
      • 6.4.5.5 China Transgenic Animal Model Market, by End User
    • 6.4.6 Japan
      • 6.4.6.1 Country Overview
      • 6.4.6.2 Japan Transgenic Animal Model Market, by Technology
      • 6.4.6.3 Japan Transgenic Animal Model Market, by Animal Type
      • 6.4.6.4 Japan Transgenic Animal Model Market, by Application
      • 6.4.6.5 Japan Transgenic Animal Model Market, by End User
    • 6.4.7 India
      • 6.4.7.1 Country Overview
      • 6.4.7.2 India Transgenic Animal Model Market, by Technology
      • 6.4.7.3 India Transgenic Animal Model Market, by Animal Type
      • 6.4.7.4 India Transgenic Animal Model Market, by Application
      • 6.4.7.5 India Transgenic Animal Model Market, by End User
    • 6.4.8 Australia
      • 6.4.8.1 Country Overview
      • 6.4.8.2 Australia Transgenic Animal Model Market, by Technology
      • 6.4.8.3 Australia Transgenic Animal Model Market, by Animal Type
      • 6.4.8.4 Australia Transgenic Animal Model Market, by Application
      • 6.4.8.5 Australia Transgenic Animal Model Market, by End User
    • 6.4.9 South Korea
      • 6.4.9.1 Country Overview
      • 6.4.9.2 South Korea Transgenic Animal Model Market, by Technology
      • 6.4.9.3 South Korea Transgenic Animal Model Market, by Animal Type
      • 6.4.9.4 South Korea Transgenic Animal Model Market, by Application
      • 6.4.9.5 South Korea Transgenic Animal Model Market, by End User
    • 6.4.10 Rest-of-the- Asia Pacific
      • 6.4.10.1 Country Overview
      • 6.4.10.2 Rest of the Asia Pacific Transgenic Animal Model Market, by Technology
      • 6.4.10.3 Rest of the Asia Pacific Transgenic Animal Model Market, by Animal Type
      • 6.4.10.4 Rest of the Asia Pacific Transgenic Animal Model Market, by Application
      • 6.4.10.5 Rest of the Asia Pacific Transgenic Animal Model Market, by End User
  • 6.5 Rest of the World
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
    • 6.5.4 Market Sizing and Forecast
      • 6.5.4.1 Rest of the World Transgenic Animal Model Market, by Technology
      • 6.5.4.2 Rest of the World Transgenic Animal Model Market, by Animal Type
      • 6.5.4.3 Rest of the World Transgenic Animal Model Market, by Application
      • 6.5.4.4 Rest of the World Transgenic Animal Model Market, by End User

7 Competitive Benchmarking and Company Profiles

  • 7.1 Key Strategies and Developments, 2023-2025
  • 7.2 Key Developments Analysis, by Company, 2023-2025
  • 7.3 Company Profiles
    • 7.3.1 Charles River Laboratories International, Inc.
      • 7.3.1.1 Overview
    • 7.3.2 Creative Biolabs
      • 7.3.2.1 Overview
    • 7.3.3 Alloy Therapeutics, Inc.
      • 7.3.3.1 Overview
    • 7.3.4 Inotiv.
      • 7.3.4.1 Overview
    • 7.3.5 Ingenious Targeting Laboratory.
      • 7.3.5.1 Overview
    • 7.3.6 HuidaGene
      • 7.3.6.1 Overview
    • 7.3.7 genOway
      • 7.3.7.1 Overview
    • 7.3.8 OmniAb, Inc.
      • 7.3.8.1 Overview
    • 7.3.9 Taconic Biosciences
      • 7.3.9.1 Overview
    • 7.3.10 Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'
      • 7.3.10.1 Overview
    • 7.3.11 Sigma-Aldrich Co. (Merck Group)
      • 7.3.11.1 Overview
    • 7.3.12 Janvier Group (Janvier Labs)
      • 7.3.12.1 Overview

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Inclusion and Exclusion
    • 8.1.4 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Transgenic Animal Model Market (by Scenario), $Million, 2024, 2028, and 2035
  • Figure 2: Global Transgenic Animal Model Market, 2024 and 2035
  • Figure 3: Top Countries, Global Transgenic Animal Model Market, $Million, 2024
  • Figure 4: Global Transgenic Animal Model Market Snapshot
  • Figure 5: Global Transgenic Animal Model Market, $Million, 2024 and 2035
  • Figure 6: Transgenic Animal Model Market (by Technology), $Million, 2024, 2028, and 2035
  • Figure 7: Transgenic Animal Model Market (by Animal Type), $Million, 2024, 2028, and 2035
  • Figure 8: Transgenic Animal Model Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 9: Transgenic Animal Model Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 10: Transgenic Animal Model Market Segmentation
  • Figure 11: Key Stakeholders of Transgenic Animal Model Market
  • Figure 12: Transgenic Animals: Timeline of Key Events
  • Figure 13: Role of Humanized Mouse Models in Development of New Precision and Personalized Medicine Strategies
  • Figure 14: Regulatory Bodies of Transgenic Animals in Europe
  • Figure 15: Regulatory Bodies of Transgenic Animals in Germany
  • Figure 16: Regulatory Process
  • Figure 17: Evolution of Transgenic Technologies
  • Figure 18: Global Drug Development Pipeline, 2019 and 2024
  • Figure 19: Major Technical Advances in Genome Editing and Delivery in Mice and Rats from 1980s to 2020s
  • Figure 20: Global Transgenic Animal Model Market (by Technology), $Million, 2024, 2028, and 2035
  • Figure 21: Transgenic Animal Model Market, CRISPR/Cas9, $Million, 2024-2035
  • Figure 22: Transgenic Animal Model Market, Microinjection, $Million, 2024-2035
  • Figure 23: Transgenic Animal Model Market, Embryonic Stem Cell Injections, $Million, 2024-2035
  • Figure 24: Transgenic Animal Model Market, Other Technologies, $Million, 2024-2035
  • Figure 25: Global Transgenic Animal Model Market (by Animal Type), $Million, 2024, 2028, and 2035
  • Figure 26: Transgenic Animal Model Market, Rodents (Mice and Rats), $Million, 2024-2035
  • Figure 27: Transgenic Animal Model Market, Rabbits, $Million, 2024-2035
  • Figure 28: Transgenic Animal Model Market, Pigs, $Million, 2024-2035
  • Figure 29: Transgenic Animal Model Market, Other Animal Types, $Million, 2024-2035
  • Figure 30: Global Transgenic Animal Model Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 31: Transgenic Animal Model Market, Drug Discovery and Development, $Million, 2024-2035
  • Figure 32: Transgenic Animal Model Market, Disease Research, $Million, 2024-2035
  • Figure 33: Transgenic Animal Model Market, Gene Function Studies, $Million, 2024-2035
  • Figure 34: Transgenic Animal Model Market, Toxicology and Safety Testing, $Million, 2024-2035
  • Figure 35: Transgenic Animal Model Market, Other Applications, $Million, 2024-2035
  • Figure 36: Global Transgenic Animal Model Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 37: Transgenic Animal Model Market, Pharmaceutical and Biotechnology Companies, $Million, 2024-2035
  • Figure 38: Transgenic Animal Model Market, Contract Research Organizations (CROs), $Million, 2024-2035
  • Figure 39: Transgenic Animal Model Market, Academic and Research Institutes, $Million, 2024-2035
  • Figure 40: North America Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 41: Europe Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 42: Asia Pacific Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 43: Rest of the World Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 44: Key Strategies and Developments, 2023-2025
  • Figure 45: Inclusion and Exclusion Criteria for Global Transgenic Animal Model Market
  • Figure 46: Data Triangulation
  • Figure 47: Top-Down and Bottom-Up Approach
  • Figure 48: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Cost of Generating New Transgenic Animals
  • Table 3: Cost of Purchasing Existing Models
  • Table 4: Additional Costs
  • Table 5: Global Transgenic Animal Model Market (by Region), $Million, 2024-2035
  • Table 6: Transgenic Animal Model Market (by Region), $Million, 2024-2035
  • Table 7: North America Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 8: North America Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 9: North America Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 10: North America Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 11: North America Transgenic Animal Model Market (by Country), $Million, 2024-2035
  • Table 12: U.S. Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 13: U.S. Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 14: U.S. Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 15: U.S. Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 16: Canada Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 17: Canada Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 18: Canada Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 19: Canada Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 20: Europe Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 21: Europe Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 22: Europe Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 23: Europe Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 24: Europe Transgenic Animal Model Market (by Country), $Million, 2024-2035
  • Table 25: U.K. Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 26: U.K. Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 27: U.K. Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 28: U.K. Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 29: Germany Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 30: Germany Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 31: Germany Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 32: Germany Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 33: France Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 34: France Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 35: France Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 36: France Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 37: Italy Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 38: Italy Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 39: Italy Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 40: Italy Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 41: Spain Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 42: Spain Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 43: Spain Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 44: Spain Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 45: Rest of the Europe Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 46: Rest of the Europe Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 47: Rest of the Europe Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 48: Rest of the Europe Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 49: Asia Pacific Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 50: Asia Pacific Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 51: Asia Pacific Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 52: Asia Pacific Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 53: Asia Pacific Transgenic Animal Model Market (by Country), $Million, 2024-2035
  • Table 54: China Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 55: China Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 56: China Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 57: China Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 58: Japan Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 59: Japan Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 60: Japan Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 61: Japan Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 62: India Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 63: India Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 64: India Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 65: India Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 66: Australia Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 67: Australia Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 68: Australia Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 69: Australia Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 70: South Korea Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 71: South Korea Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 72: South Korea Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 73: South Korea Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 74: Rest of the Asia Pacific Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 75: Rest of the Asia Pacific Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 76: Rest of the Asia Pacific Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 77: Rest of the Asia Pacific Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 78: Rest of the World Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 79: Rest of the World Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 80: Rest of the World Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 81: Rest of the World Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 82: Key Strategies and Developments, 2023-2025